Low HDL-C, High TG Increase Risk for Diabetic Kidney Disease

Share this content:
Low HDL-C, High TG Increase Risk for Diabetic Kidney Disease
Low HDL-C, High TG Increase Risk for Diabetic Kidney Disease

WEDNESDAY, Oct. 12, 2016 (HealthDay News) -- For patients with diabetes, low high-density lipoprotein cholesterol (HDL-C) and high triglyceride (TG) levels are associated with increased risk of diabetic kidney disease (defined as low estimated glomerular filtration rate [eGFR], an eGFR reduction >30 percent, and/or albuminuria), according to a study published online Oct. 4 in Diabetes Care.

Giuseppina T. Russo, M.D., Ph.D., from the University of Messina in Italy, and colleagues conducted an observational retrospective study involving 15,362 patients attending Italian diabetes centers with baseline eGFR ≥60 mL/min/1.73 m², normoalbuminuria, and low-density lipoprotein cholesterol ≤130 mg/dL completing a four-year follow-up.

The researchers found that TG ≥150 mg/dL correlated with increases in the risk of low eGFR (26 percent), eGFR reduction >30 percent (29 percent), albuminuria (19 percent), and developing one abnormality (35 percent). HDL-C <40 mg/dL in men and <50 mg/dL in women correlated with increases in the risk of low eGFR (27 percent), eGFR reduction >30 percent (28 percent), albuminuria (24 percent), and developing one abnormality (44 percent). The correlations persisted when TG and HDL-C were assessed as continuous variables, and were attenuated by adjustment for multiple confounding variables.

"In a large population of outpatients with diabetes, low HDL-C and high TG levels were independent risk factors for the development of diabetic kidney disease over four years," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »